CYTOGEN'S QUADRAMET STUDY RESULTS REPORTED

Cytogen Corporation has reported preclinical data on Quadramet (samarium Sm-153 lexidronam) in combination with bortezomib. The combination demonstrated broad anticancer activity in a murine myeloma model, including greatly prolonged median survival, rapidly reduced clonogenicity of bone-marrow resident 5TGM1 cells, slowed elevation of serum myeloma-associated paraprotein levels, and longer term preservation of bone mineral density.

In vitro studies demonstrated synergistic killing of myeloma cell lines with the combination of QUADRAMET and bortezomib. In vivo studies demonstrated that the combination therapy greatly prolonged median survival of mice and was well-tolerated.